oncology– tag –
-
Cancer Treatment Introductory–to–Basic Series – Part 6
Living with Recurrence and Metastasis: Cancer as a Long-Term Journey In Part 5, we explored why some cancers are considered “more curable” or “harder to cure,” focusing on the roles of stage, biology, and overall health. In this Part 6, ... -
Oncology Drug Approval News Flash: FDA approves perioperative pembrolizumab plus enfortumab vedotin-ejfvfor cisplatin-ineligible muscle invasive bladder cancer (MIBC)
On November 21, 2025, the U.S. FDA approved pembrolizumab (Keytruda / Keytruda Qlex) in combination with enfortumab vedotin-ejfv (Padcev) as neoadjuvant and adjuvant therapy for adults with muscle invasive bladder cancer (MIBC) who are e... -
Cancer Treatment Introductory–to–Basic Series – Part 4
Basics of Particle Therapy (Proton and Heavy-Ion): How It Differs from X-ray Radiotherapy In Part 3, we explored the basics of X-ray–based radiotherapy, including external beam radiation, brachytherapy, and high-precision techniques such... -
Oncology Drug Approval News Flash: FDA Grants Full Approval to Tarlatamab-dlle for ES-SCLC and Accelerated Approval to Sevabertinib for HER2-Mutated NSCLC
On November 19, 2025, the U.S. Food and Drug Administration (FDA) granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen) for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease progressed after platinum... -
Oncology Drug Approval News Flash: FDA Approves Selumetinib (KOSELUGO) for Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
On November 19, 2025, the U.S. Food and Drug Administration (FDA) approved selumetinib (KOSELUGO, AstraZeneca) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Previously appro... -
Oncology Drug Approval News Flash: FDA Approves Epcoritamab-bysp (Epkinly) with R² for Relapsed or Refractory Follicular Lymphoma
On November 18, 2025, the U.S. Food and Drug Administration (FDA) approved epcoritamab-bysp (Epkinly, Genmab / AbbVie) in combination with lenalidomide and rituximab (R²) for adults with relapsed or refractory follicular lymphoma (FL). T... -
Cancer Treatment: Introductory–to–Basic Series – Part 3
Basics of Radiotherapy: How It Works, Types, and Roles in Cancer Care In Part 1, we drew an overall map of cancer treatment and looked at why some cancers are easier or harder to cure. In Part 2, we explored how surgery, drug therapy, an... -
Cancer Treatment: Introductory–to–Basic Series – Part 2
How Surgery, Drug Therapy, and Immunotherapy Work Together – And Why Cancer Sometimes Comes Back Lead In Part 1, we drew a broad map of cancer treatment and looked at why some cancers are easier to cure than others. In this Part 2, we go... -
Cancer Treatment: Introductory–to–Basic Series – Part 1
Understanding the Overall Picture of Cancer Treatment and Why Some Cancers Are “Easier” or “Harder” to Cure “Can cancer really be cured?” “If it comes back, does that mean it is over?” These are among the most common and most painful que... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 6 Final: BRD4 and CDK Crosstalk — The Future of Super-Enhancer Targeting)
From Part 1 through Part 5, we explored CDK7/8/9/12/13/11 and their roles in transcriptional regulation. In this final installment, we turn to BRD4, a pivotal co-regulator that interacts closely with CDKs and controls super-enhancer–driv... -
Oncology Drug Approval News Flash: FDA Approves Poherdy (pertuzumab-dpzb) as the First Interchangeable Biosimilar to Perjeta
On November 13, 2025, the U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics) as the first interchangeable biosimilar to Perjeta (pertuzumab, Genentech). This marks a historic step in ex... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 5: CDK11 — Pause-Checkpoint and Emerging Therapeutic Potential)
In Part 4, we examined CDK12/13 and their role in DNA repair and synthetic lethality. Here in Part 5, we focus on CDK11, a kinase that has recently gained attention for its role as a pause-checkpoint regulator in transcription, preceding... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 4: CDK12 & CDK13 — DNA Repair and Synthetic Lethality Strategies)
In Parts 1–3, we reviewed CDK7/8 and CDK9. Here in Part 4, we turn to CDK12 and CDK13, transcriptional kinases that stabilize elongation of long DNA repair genes. They serve as “guardians” of genome stability and represent key players in... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 3: CDK9 — The Bottleneck of Transcription Elongation and Clinical Development)
In Parts 1 and 2, we introduced CDK7 and CDK8 in transcription initiation. Here in Part 3, we focus on CDK9, the central kinase controlling the transition from paused RNA polymerase II (Pol II) to productive elongation. Among transcripti... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 2: CDK7 & CDK8 — Gatekeepers of Transcription Initiation and Emerging Therapeutics)
In Part 1, we reviewed the fundamentals of transcription and the CDK family. In this article, we focus on CDK7 and CDK8, two kinases that act at the transcriptional “starting line.” While both regulate initiation, their roles and drug di... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 0: Introduction and Overview)
This series focuses on the transcriptional machinery as an emerging target for cancer therapy, highlighting CDK (Cyclin-Dependent Kinases) families involved in transcription and BRD4. While CDK4/6 inhibitors have already transformed onco... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 1: Introduction — Overview of Transcription and CDK Families)
This series will explore the latest drug discovery trends targeting the transcriptional machinery. In Part 1, we provide an introduction: what transcription is, how CDKs regulate it, and why transcriptional CDKs are emerging as hot targe... -
Oncology Drug Approval News Flash: FDA Approves Darzalex Faspro for High-Risk Smoldering Multiple Myeloma
On November 6, 2025, the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj, Janssen Biotech, Inc.) for the treatment of adults with high-risk smoldering multiple myeloma (SMM). This mark... -
Series: Decoding Cancer-Associated Cachexia — From Basics to Breakthroughs | Part 6 (Finale)
What’s Next — GDF15 Blockade and the Era of Precise Phenotypes Our finale focuses on near-future therapies and trial design. Beyond “weight,” we target phenotype × mechanism and build evidence that actually changes care. 3 takeaways Dire... -
Series: Decoding Cancer-Associated Cachexia — From Basics to Breakthroughs | Part 5
What Works Today — Nutrition, Exercise, Anti-inflammation, and Current Drugs Part 5 is a how-to guide. We align home and clinic workflows and run nutrition, resistance exercise, inflammation/symptom control as a package. Medications are ...
